Market Research Report

GCC Oncology/Cancer Drugs Market Research Report: Forecast (2023-2028)

By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Others), By Application Breast Cancer, (Lung Cancer, Kidney Cancer, Liver cancer, Ovarian Cancer, Prost...ate Cancer, Skin Cancer, Pancreatic Cancer, Colorectal, Blood Cancer, Others), By Country (Saudi Arabia, The UAE, Qatar, Kuwait, Bahrain, Oman), By Company (Hoffmann-La Roche Ltd., Johnson & Johnson Middle East FZ LLC, Pfizer International Corporation, Merck Serono Middle East FZ-Ltd., AbbVie Biopharmaceuticals GmbH, AstraZeneca Gulf FZ LLC, Bayer Middle East FZE, Amgen, Inc., Astellas MENA/SSA, Others) Read more

  • Healthcare
  • Mar 2023
  • 187
  • PDF, Excel, PPT

Market Definition

Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies.

Market Insights & Analysis: GCC Oncology/Cancer Drugs Market (2023-28)

The GCC Oncology/Cancer Drugs Market is projected to grow at a considerable CAGR during the forecast period, i.e., 2023-28. This is due to the rising incidences of patients diagnosed with cancer in the nations like the UAE, Saudi Arabia, Kuwait, etc., and the surging initiative to reduce the number of deaths due to cancer. As per the World Health Organization, a total of around 21.4% of breast cancer cases were reported in 2020 in the UAE, whereas the same around 14.5% of colorectal cancer, and nearly 12.5% of prostate cancer were reported among men in the country.

Report Coverage Details
Study Period Historical Data: 2018-21
Base Year: 2022
Forecast Period: 2023-28
Country Covered Saudi Arabia, The UAE, Qatar, Kuwait, Bahrain, Oman
Key Companies Profiled Hoffmann-La Roche Ltd., Johnson & Johnson Middle East FZ LLC, Pfizer International Corporation, Merck Serono Middle East FZ-Ltd., AbbVie Biopharmaceuticals GmbH, AstraZeneca Gulf FZ LLC, Bayer Middle East FZE, Amgen, Inc., Astellas MENA/SSA, Others
Unit Denominations USD Million/Billion

 

In addition to this, Saudi Arabia also registered around 14.4% of colorectal cancer cases among the population in 2020, according to the World Health Organization. Therefore, the rising prevalence of several types of cancer cases among the men and women population of the GCC nations is estimated to create the potential demand for oncology/cancer drugs in the forecast years, thereby creating a positive market outlook for the growth of the GCC Oncology/Cancer Drugs market from 2023 to 2028.

In line with this, the surging investments by the governments in the region to support and enhance the healthcare facilities of the hospitals, clinics, etc., are resulting in a significant demand for a variety of oncology/cancer drugs. Also, the uprising healthcare infrastructure developments in the countries like the UAE, Saudi Arabia, etc., would necessitate the demand for these treatment drugs in the forecast years, further enhancing the GCC Oncology/Cancer Drugs Market size. For instance:

  • In 2023, the government of Saudi Arabia Announced to invest around USD65 billion to develop the country’s healthcare infrastructure.

GCC Oncology/Cancer Drugs Market Research Report: Forecast (2023-2028)

Market Dynamics

Key Driver: Growing Prevalence of Various Cancer Cases to Uplift the Oncology/Cancer Drugs Market

The GCC nations have been witnessing a massive surge in several types of cancer cases including lung cancer, breast cancer, colorectal cancer, prostate cancer, etc. The prominent factor behind the increasing cases of lung cancer in the GCC nations remains the habit of tobacco smoking among the men population. The smoking prevalence has been subsequently leading to a large number of lung cancer cases mainly in Saudi Arabia, Bahrain, and Oman. For instance, in 2020, around 6% male of Saudi Arabia were diagnosed with lung cancer, as per the World Health Organization. Thus, the growing prevalence of different types of cancers among the GCC population would facilitate the requirement for oncology/cancer drugs in the forthcoming period. 

Growth Opportunity: Escalating Governments Initiatives to Boost the Market Growth

The GCC nations have been witnessing a massive surge in several types of cancer cases including lung cancer, breast cancer, colorectal cancer, prostate cancer, etc. The prominent factor behind the increasing cases of lung cancer in the GCC nations remains the habit of tobacco smoking among the men population. The smoking prevalence has been subsequently leading to a large number of lung cancer cases mainly in Saudi Arabia, Bahrain, and Oman. For instance, in 2020, around 6% of males in Saudi Arabia were diagnosed with lung cancer, as per the World Health Organization. Thus, the growing prevalence of different types of cancers among the GCC population would facilitate the requirement for oncology/cancer drugs in the forthcoming period. 

Market Segmentation

Based on Therapy:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Hormonal Therapy
  • Others

Based on Therapy, Targeted Therapy is anticipated to attain the highest CAGR in the forthcoming years. The growth is attributed to bolstering cases of breast cancer. Targeted therapy is widely used for the treatment of breast cancer by targeting cellular processes to stop the growth of cancer cells along with being highly efficient and having high survival rates.

Based on Application:

  • Breast Cancer
  • Lung Cancer
  • Kidney Cancer
  • Liver cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Skin Cancer
  • Pancreatic Cancer
  • Colorectal
  • Blood Cancer
  • Others

Breast cancer is among the leading reasons for the death of women in the region. In UAE, 1,054 new cases of breast cancer were registered in 2018. Women around the age of 40 and above are likely to develop breast cancer. To reduce the overall mortality rate, various steps are being taken by the governments for the production of oncology drugs for breast cancer. Besides this, numerous Breast Cancer Awareness and Prevention programs are also initiated by the governments in the region to spread awareness amongst women about the disease and to enable them toward early detection and diagnosis, prevention, and treatment methods. Thus, these factors are expected to catalyze the market growth of Oncology/Cancer Drugs in the forecast period.

Regional Projection

Geographically, the GCC Oncology/Cancer Drugs Market expands across:

  • Saudi Arabia
  • The UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Oman

Among all the nations, the UAE is expected to be a hotspot for the demand for oncology/cancer drugs in the forecast years, owing to the massive surge in the cases of breast cancer among the female population of the country. In addition, the malignancy of breast cancer cases in the UAE has led to the launch of several awareness campaigns for the detection of breast cancer among the female population. For instance, in 2022, Sheikh Shakhbout Medical City (SSMC) in Abu Dhabi launched a new support group for breast cancer patients as part of its awareness campaign to combat the disease. Furthermore, the growing focus of the UAE government to amplify medical tourism in the country is also predicted to accelerate the growth of the GCC Oncology/Cancer Drugs market from 2023 to 2028. 

Do You Require Further Assistance?

  1. The sample report seeks to acquaint you with the layout and the overall research content.
  2. The deliberate utilization of the report may further streamline operations while maximizing your revenue.
  3. To gain an unmatched competitive advantage in your industry, you can customize the report by adding more segments and specific countries suiting your needs.
  4. For a better understanding of the contemporary market scenario, feel free to connect to our knowledgeable analysts.

Frequently Asked Questions

   A. The GCC Oncology/Cancer Drugs Market is predicted to grow at a considerable CAGR during 2023-28.

   A. The rising prevalence of breast, colorectal, lung cancer cases among the GCC population is expected to drive the GCC Oncology/Cancer Drugs Market during 2023-28

   A. The top players in the GCC Oncology/Cancer Drugs Market are Hoffmann-La Roche Ltd., Johnson & Johnson Middle East FZ LLC, Pfizer International Corporation, Merck Serono Middle East FZ-Ltd., AbbVie Biopharmaceuticals GmbH, AstraZeneca Gulf FZ LLC, Bayer Middle East FZE, Amgen, Inc., Astellas MENA/SSA, and Others.

   A. Breast Cancer is the leading application in the GCC Oncology/Cancer Drugs Market.

   A. The UAE would present growth prospects in the GCC Oncology/Cancer Drugs Market during 2023-28.

   A. The hospitals, Clinics, Diagnostic Centers, etc., are the industry's potential end-users.

   A. The surging government spending in the GCC region to enhance healthcare infrastructure and facilities would likely create a lucrative market opportunity for the growth of the GCC Oncology/Cancer Drugs Market through 2028.

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. GCC Oncology/Cancer Drugs Market Trends & Insights
  5. GCC Oncology/Cancer Drugs Market Dynamics
    1. Drivers
    2. Challenges
  6. GCC Oncology/Cancer Drugs Market Regulations & Policies
  7. GCC Oncology/Cancer Drugs Market Hotspots & Opportunities
  8. GCC Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Therapy
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted Therapy
        4. Hormonal Therapy
        5. Others
      2.  By Application
        1. Breast Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Liver cancer
        5. Ovarian Cancer
        6. Prostate Cancer
        7. Skin Cancer
        8. Pancreatic Cancer
        9. Colorectal
        10. Blood Cancer
        11. Others
      3. By Country
        1. Saudi Arabia
        2. The UAE
        3. Qatar
        4. Kuwait
        5. Bahrain
        6. Oman
      4. By Company
        1. Competition Characteristics
        2. Market Share of Leading Companies, By Revenues
  9. Saudi Arabia Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Therapy
      2. By Application
  10. The UAE Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Therapy
      2. By Application
  11. Qatar Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Therapy
      2. By Application
  12. Kuwait Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Therapy
      2. By Application
  13. Bahrain Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Therapy
      2. By Application
  14. Oman Oncology/Cancer Drugs Market Outlook, 2018-2028F
    1. Market Size & Analysis
    2. Market Size & Analysis
      1. By Revenues (USD Million)
    3. Market Share & Analysis
      1. By Therapy
      2. By Application
  15. GCC Oncology/Cancer Drugs Industry- Market Attractiveness Indexing, 2018-2028F
  16. GCC Oncology/Cancer Drugs Market Key Strategic Imperatives for Growth & Success
  17. Competition Outlook
    1. Competition Matrix
      1. Brand Specialization
      2. Target Markets
      3. Target End Users
      4. Research & Development
      5. Strategic Alliances
      6. Strategic Initiatives
    2. Company Profiles
      1. Hoffmann-La Roche Ltd.
      2. Johnson & Johnson Middle East FZ LLC
      3. Pfizer International Corporation
      4. Merck Serono Middle East FZ-Ltd.
      5. AbbVie Biopharmaceuticals GmbH
      6. AstraZeneca Gulf FZ LLC
      7. Bayer Middle East FZE
      8. Amgen, Inc.
      9. Astellas MENA/SSA
      10. Others
  18. Disclaimer


GCC Oncology and Cancer Drugs Market Segmentation